

Short Name	Full Title + Study Description	Type	Investigator	Contact
<b>Reprise IV</b>	<b>Repositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of Lotus Edge™ Valve System in Intermediate Surgical Risk Subjects-REPRISE IV</b>  <i>To evaluate safety and effectiveness of the LOTUS Edge Valve System when used with the Lotus of iSleeve Introducer Sets for transcatheter aortic valve replacement (TAVR) in symptomatic subjects with severe aortic stenosis who are considered at intermediate risk for surgical valve replacement including those who have a bicuspid native valve</i>	Device	<a href="#">Dr. William Merhi</a>	Karen Postema <a href="mailto:Karenl.postema@spectrumhealth.org">Karenl.postema@spectrumhealth.org</a> 616.391.9356
<b>TAVR Low Risk Bicuspid</b>	<b>TAVR Low Risk Bicuspid:Transcatheter Aortic Valve Replacement(TAVR) with Medtronic TAVR System in Patients with Severe Bicuspid Aortic Valve Stenosis and at Low Predicted Risk of Mortality with Surgical Aortic Valve Replacement (SAVR)</b>  <i>Primary Objective:To Evaluate the procedural safety and efficacy of the Medtronic TAVR system in patients with bicuspid aortic anatomy and severe aortic stenosis at low risk for SAVR. Patient Population:Severe aortic stenosis subjects with bicuspid aortic anatomy and an indication for SAVR with a bioprosthesis whose predicted risk of mortality at 30 days is &lt;3% per multidisciplinary local heart team assessment.</i>	Device	<a href="#">Dr. William Merhi</a>	Elizabeth Helm <a href="mailto:Elizabeth.Helm@spectrumhealth.org">Elizabeth.Helm@spectrumhealth.org</a> 616.486.2080